Prolactinomas

New England Journal of Medicine

Volumn 362, Issue 13, 2010, Pages 1219-1226

  Klibanski, Anne ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; GONADORELIN; PROLACTIN; QUINAGOLIDE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

ALCOHOL INTOLERANCE; ANXIETY; CANCER RADIOTHERAPY; CANCER SURGERY; CAVERNOUS SINUS; COLD SENSITIVITY; CONSTIPATION; DEPRESSION; DIZZINESS; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS FUNCTION; LIBIDO DISORDER; LUTEAL PHASE; MICROADENOMA; NAUSEA; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; ORTHOSTATIC HYPOTENSION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PSYCHOSIS; REVIEW; SELLA TURCICA TUMOR; SIDE EFFECT; TESTIS ATROPHY; TESTIS SIZE; TRANSSPHENOIDAL SURGERY; VALVULAR HEART DISEASE; VASOSPASM; ADULT; BLOOD; FEMALE; HYPOPHYSIS TUMOR; MALE; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; VISUAL FIELD;

ADULT; BROMOCRIPTINE; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROLACTIN; PROLACTINOMA; VISUAL FIELDS;

EID: 77950475252     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp0912025     Document Type: Review

References (50)

1. Melmed S. The pituitary. 2nd ed. Malden, MA: Blackwell, 2002.
2. Pituitary adenomas and oral contraceptives: a multicenter case-control study. Fertil Steril 1983;39:753-60.
3. Bergh T, Skarin G, Nillius SJ, Wide L. Pulsatile GnRH therapy - an alternative successful therapy for induction of ovulation in infertile normo-and hyperprolactinaemic amenorrhoeic women with pituitary tumours. Acta Endocrinol (Copenh) 1985;110:440-4.
4. Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988;67:124-30.
5. Vestergaard P, Jørgensen JO, Hagen C, et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case-control study. Clin Endo - crinol (Oxf) 2002;56:159-67.
6. Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986;104:777-82.
7. Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978;299:847-52.
8. Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS. Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary 2009;12:186-9.
9. Nunley WC, Urban RJ, Kitchin JD, Bateman BG, Evans WS, Veldhuis JD. Dynamics of pulsatile prolactin release during the postpartum lact ational period. J Clin Endocrinol Metab 1991;72:287-93.
10. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28: Suppl 2: 55-68.
11. Correll CU, Carlson HE. Endocr ine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:771-91.
12. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80 : 1050-7.
13. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screen ing for m acroprolact in. J Clin Endo - crinol Metab 2005;90:3927-32. (Pubitemid 41058153)
14. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996;44:305-9.
15. March CM, Kletzky OA, Davajan V, et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981;139:835-44. (Pubitemid 11126045)
16. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1996;45:299-303. (Pubitemid 26306698)
17. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective ana lysis. J Clin Endocrinol Metab 1989;68:412-8. (Pubitemid 19052886)
18. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 2001;54:295-300. (Pubitemid 32234192)
19. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59 : 671-3. (Pubitemid 23086332)
20. Verhelst J, Abs R, Maiter D, et al. Cab - ergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-22.
21. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-9. (Pubitemid 24299871)
22. Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986;315:542-6. (Pubitemid 16014768)
23. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698-705.
24. Biller BM, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338-43.
25. Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. JCl in Endocrinol Metab 2001;86:5256-61. (Pubitemid 33070245)
26. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876-83. (Pubitemid 27106605)
27. Redfield MM, Nicholson W J, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlat ions. Ann Intern Med 1992;117:50-2.
28. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine ag onists for Parkinson's disease. N Engl J Med 2007;356:39-46. (Pubitemid 46041752)
29. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and therisk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. (Pubitemid 46041751)
30. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
31. Nachtigall LB, Valassi E, Lo J, et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) 2010;72:53-8.
32. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009;70:104-8.
33. Colao A, Galderisi M, DiSarno A, et al. Increased pre valence of tricuspid reg urgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93:3777-84.
34. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 2008;31:1119-23.
35. Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002;87:3578-82.
36. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyp er prol ac t inemia. N Engl J Med 2003;349:2023-33. (Pubitemid 37448925)
37. Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007;67:426-33. (Pubitemid 47283843)
38. Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 2005;63:26-31. (Pubitemid 40966398)
39. Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:43-51.
40. Mori H, Mori S, Saitoh Y, et al. Effects of bromocriptine on prolactin-secreting pit uit ar y adenomas: mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis. Cancer 1985;56:230-8. (Pubitemid 15031638)
41. Barker FG II, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003;88:4709-19. (Pubitemid 37357516)
42. Thomson JA, Gray CE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery 2002;50:36-40.
43. Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983;309:280-3. (Pubitemid 13074919)
44. Jezková J, Hána V, Krsek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf) 2009;70:732-41.
45. Molitch ME. Pregnancy and the hyperprolact i nem ic woman. N Engl J Med 1985;312:1364-70.
46. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987;65:823-7. (Pubitemid 17123339)
47. Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008;68:66-71. (Pubitemid 350243483)
48. Rasmussen C, Bergh T, Nillius SJ, Wide L. Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine- induced pregnancy. Fertil Steril 1985;44:31-4. (Pubitemid 15000544)
49. Valassi E, Klibanski A, Biller BMK. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010 February 3 (Epub ahead of print).
50. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-73. (Pubitemid 44079693)